media – Page 35 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

New Drug Combos Could Cut Heart Failure Mortality by 60%

Optimized treatment can reduce the mortality risk for chronic heart failure (HF) by as much as 60%. The role of appropriate drug combinations and rapid diagnosis was discussed at the 91st Annual German Society of Cardiovascular Medicine Annual Conference. “It is important to start drug treatment for HF immediately after diagnosis, in parallel with investigating the underlying causes, as the benefits of treatment appear very quickly,” said Birgit Assmus, MD, cardiologist and head of the Heart Failure Department of the University Hospital of Giessen and Marburg, Marburg, Germany. Recommended Treatment For HF with reduced ejection fraction (HFrEF) and a left ventricular ejection fraction (LVEF) ≤ 40%, as well as for HF with moderately reduced ejection fraction (LVEF between 41% and 49%), the 2021 European Society of Cardiology (ESC) guidelines recommend a quadruple combination of angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor/neprilysin inhibitors (ARNI), beta-blockers, mineralocorticoid receptor antagonists (MRAs), and sodium-glucose ...
- Source: drugdu
- 111
- May 16, 2025
GSK Makes a Big Liver Disease Move With $1.2B Deal for Phase 3-Ready MASH Drug

GSK is acquiring Boston Pharmaceuticals’ efimosfermin, which posted Phase 2 results showing improvement in fibrosis and resolution of MASH. GSK said this fusion protein will complement an siRNA drug it is currently developing for liver diseases. GSK is expanding its prospects in hepatology, paying $1.2 billion to acquire a drug that goes after a clinically validated liver target but with a dosing advantage that could give it a competitive edge against rivals further along in their development of therapies for the fatty liver disease MASH. The agreement announced Wednesday brings GSK efimosfermin alfa, a Boston Pharmaceuticals drug that is ready for Phase 3 testing. In addition to metabolic dysfunction-associated steatohepatitis (MASH), GSK plans to develop the drug for alcohol-related liver disease. Both are forms of steatotic liver disease, in which fat buildup damages the organ. MASH leads to inflammation and liver scarring, also called fibrosis. Though the history of ...
- Source: drugdu
- 124
- May 16, 2025
Shutaishen’s STSP-0601 for injection obtains drug production license

On May 13, Shutaishen, an announcement was issued that the company’s subsidiary Jiangsu Beijietai Biotechnology Co., Ltd. (hereinafter referred to as “Beijietai”) recently obtained a drug production license issued by the Jiangsu Provincial Food and Drug Administration. The announcement stated that Beijietai has obtained the “Drug Production License” and will be commissioned to produce therapeutic biological products.(STSP-0601 for injection is limited to registration and application use) and is not expected to have a significant impact on the company’s current performance. The relevant products can only be commercially produced after obtaining the drug marketing approval number. https://finance.eastmoney.com/a/202505143404500613.html
- Source: drugdu
- 184
- May 16, 2025
Entered into an exclusive licensing agreement with Cipla for irinotecan liposome injection

CSPC Pharmaceutical Group announced on the Hong Kong Stock Exchange that it has entered into an exclusive license agreement with Cipla USA, Inc. (“Cipla”) for the commercialization of the company’s irinotecan liposome injection in the United States. Under the terms of the agreement, the company agreed to grant Cipla an exclusive license to commercialize the product in the region. The company will receive an initial payment of US$15 million and is also entitled to receive potential first commercial sales and regulatory milestone payments of up to US$25 million and potential additional commercial sales milestone payments of up to US$1.025 billion, as well as double-digit tiered sales commissions based on the product’s annual net sales in the region. Irinotecan is currently used to treat a variety of solid tumors, such as metastatic pancreatic cancer, colorectal cancer, lung cancer and cervical cancer, and is a component of a variety of combination therapies ...
- Source: drugdu
- 113
- May 16, 2025
Sanming Alliance Consumables Procurement is about to be implemented

Recently, the Hainan Provincial Medical Security Bureau issued the “Notice on the Implementation of the Selected Results of the Centralized Procurement of Medical Consumables for the “Six Diseases Co-management” of the Sanming Alliance” (hereinafter referred to as the “Notice”), which will implement the selected results of the centralized procurement of three types of consumables from May 20, 2025. A total of 43 companies were selected in this centralized procurement of three types of consumables. The agreed quantities and bidding prices of some products are as follows: According to the relevant notice issued by the Sanming Procurement Alliance earlier, the procurement varieties and requirements are as follows: It is reported that this centralized procurement quotation divides the products into groups A and B. In the same product category, each applicant can only declare one price, covering all products that meet the application conditions under the product category. Among them, the ...
- Source: drugdu
- 82
- May 16, 2025
All products shipped to China will be priced higher

On May 11, international giant Merck issued a notice stating that due to the impact of the Sino-US trade tariff policy, a temporary surcharge will be imposed on all product orders shipped to China starting from May 12. Merck, as a global technology giant with a profound history, has business in three key areas: life sciences, pharmaceuticals and health, and electronic technology. Since its founding in 1668, Merck, headquartered in Germany, has occupied a pivotal position in the global market with its outstanding technological innovation capabilities and extensive product portfolio. The Chinese market is of great significance to Merck, whose development history in this land can be traced back more than 90 years ago. Currently, Merck has nearly 4,500 employees in China, with a wide range of business layout, including 21 registered companies in Beijing, Shanghai, Wuxi, Suzhou, Nantong, Hong Kong, etc., building a complete industrial chain integrating R&D, production ...
- Source: drugdu
- 74
- May 16, 2025
【EXPERT Q&A】How to view the compliance of pharmaceutical companies’ records?

Drugdu.com expert’s response: Record compliance in pharmaceutical enterprises is a core element in safeguarding drug quality, ensuring patient medication safety, and maintaining corporate reputation and market competitiveness. The following provides an in-depth analysis from the perspectives of importance, influencing factors, challenges, and coping strategies: I. The Importance of Record Compliance in Pharmaceutical Enterprises Regulatory Compliance and Legal Liabilities: Pharmaceutical companies must strictly adhere to regulations such as the “Drug Administration Law” and “Good Manufacturing Practice (GMP).” Record compliance is a core requirement of regulatory oversight. Inaccurate or missing records may expose enterprises to severe consequences, including hefty fines, product recalls, or even license revocation. Drug Quality and Safety Assurance: Complete and accurate records form the basis for traceability throughout the entire drug production process. For instance, the compliance of records related to raw material procurement, production processes, and inspection data directly impacts whether drug quality meets standards. Any missing records in any环节 ...
- Source: drugdu
- 91
- May 16, 2025
Tilpotide wins head to head over semaglutide, with a GLP-1 market worth billions, ushering in the era of “duopoly”

The competition in the GLP-1 track is becoming increasingly fierce, and the game between giants to grab the market is becoming more and more obvious. On May 11th, Eli Lilly and Company released research data on SURMUNT-5, which exploded like a bombshell in the global weight loss drug market. Its new GLP-1/GIP dual receptor agonist, Tilpotide, outperformed Novo Nordisk’s semaglutide in key indicators such as weight loss of 20.2% vs 13.7% and waist circumference reduction of 18.4cm vs 13.0cm. According to the data disclosed by Eli Lilly, in the primary endpoint of the study, telapride achieved a relative weight loss of 1.47 times compared to semaglutide. According to research data based on treatment plan estimation goals, at week 72, the average weight loss rate achieved by telmisartan was 20.2%, while that of semaglutide was 13.7%. The average weight loss of the Tilpotide group was 22.8kg, and the average weight loss ...
- Source: drugdu
- 130
- May 15, 2025
The continuous development of innovative drugs by Yuanda Pharmaceutical has attracted capital attention, with a stock price increase of over 38% in 5 trading days

On the evening of May 12th, Yuanda Pharmaceutical once again disclosed the new progress of a globally innovative radionuclide coupled drug TLX591 CDx under research. The Phase III clinical trial of this drug in China has been completed with all patients enrolled for administration, and it is planned to submit a new drug application for market launch in China this year. This is the third major innovative research and development progress announced by Yuanda Pharmaceutical since May 6th. From May 7th to May 12th, the stock price of Yuanda Pharmaceutical rose strongly and reached a historical high of HKD 8.95 per share on May 12th. On May 13th, the stock price slightly fell, and as of the close, the stock price was HKD 8.29 per share, with a cumulative increase of 38.4% from May 7th to May 13th. This year, with the recovery of pharmaceutical stocks, the position of innovative ...
- Source: drugdu
- 80
- May 15, 2025
FDA and RFK Jr. Aim to Remove Ingestible Fluoride Products Used to Protect Kids’ Teeth

WASHINGTON (AP) — U.S. health regulators announced an effort Tuesday to phase out ingestible fluoride supplements sometimes used to strengthen children’s teeth, opening a new front in Health Secretary Robert F. Kennedy Jr.’s effort against a mainstay of dental care. The Food and Drug Administration said it will conduct a scientific review of the children’s products by late October with the aim of removing them from the market. Formally withdrawing medical products requires a lengthy rulemaking process that can take years. Instead, the FDA will ask manufacturers to voluntarily pull their products, according to an administration official. Fluoride tablets and lozenges are sometimes recommended for children and teens at increased risk of tooth decay or cavities because of low fluoride in their local drinking water. Companies also sell drops for babies. FDA Commissioner Marty Makary said the products pose a risk when swallowed because they may interfere with healthy gut ...
- Source: drugdu
- 132
- May 15, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.